EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial



Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial



Hepatology 7(6): 1278-1284



Lactitol (beta-galactosido-sorbitol) is a nonabsorbable disaccharide available as a powder which, in open comparison, is as effective as lactulose in the treatment of chronic hepatic encephalopathy, but is better tolerated. Twenty-five cirrhotic patients experiencing 28 episodes of acute hepatic encephalopathy were randomized blindly to treatment with either lactitol (n = 15) or lactulose (n = 13). The sugars were dispensed in solutions identical in appearance, taste and pH and of similar osmolarity, which contained either 66.7 gm per 100 ml lactitol or 66.7 ml (44.5 gm) per 100 ml lactulose syrup. The initial dose of 0.75 ml per kg was adjusted to produce two semisoft stools per day. Patients were assessed every 12 hr for 5 days. There were no significant differences in sex ratio, age, body weight, clinical status, duration and extent of coma, etiology of liver disease or of hepatic encephalopathy between the two groups of patients on entry to the trial. An adequate catharsis was obtained with an equivalent mean (+/- 1 S.D.) daily dose of 26 +/- 5 gm lactitol or 31 +/- 7 ml (21 +/- 5 gm) lactulose syrup. During the trial, significant improvements occurred in clinical status and psychometric performance and in the electroencephalogram mean cycle frequencies in the majority of patients in both groups. At the end of the trial, 67% of the patients in the lactitol group and 69% of the lactulose group were clinically normal. However, patients treated with lactitol responded significantly more quickly than patients treated with lactulose.

(PDF emailed within 0-6 h: $19.90)

Accession: 040548773

Download citation: RISBibTeXText

PMID: 3315932

DOI: 10.1002/hep.1840070617



Related references

Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy a double blind randomized cross over study. Journal of Hepatology 4(2): 236-244, 1987

Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients a randomized crossover study. Journal of Hepatology 8(2): 208-217, 1989

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, 2002

Treatment of acute hepatic encephalopathy with rifaximin in comparison with lactitol A multi-centre, double-blind, double-dummy, randomized controlled trial. Journal of Hepatology 30(SUPPL 1): 81, 1999

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, January, 2003

Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. Journal of Hepatology 8(2): 208-217, 1989

Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Digestive and Liver Disease 32(4): 335-338, 2001

Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double blind randomized placebo controlled study. Digestive & Liver Disease 32(4): 335-338, 2000

Lactitol in treatment of subclinical hepatic encephalopathy A double-blind placebo-controlled randomised trial. Chinese Medical Journal (English Edition) 111(2): 135, 1998

Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy a randomized cross over study. Journal Of Hepatologypl. 1: S179, 1988

Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose. Hepato-Gastroenterology 37(5): 524-527, 1990

Lactitol in the treatment of severe chronic hepatic encephalopathy a randomized cross over comparison with lactulose. Journal of Hepatology 7(SUPPL 1): S168, 1988

Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16(1): 138-144, 1992

Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. Middle East Journal of Digestive Diseases 9(1): 12-19, 2017

Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Digestive Diseases and Sciences 32(12): 1345-1353, 1987